Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-1 Antibodies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06809517
What this trial is testing

Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis

Who this might be right for
Leptomeningeal MetastasisIntrathecal Drug Delivery
Guangzhou Medical University 34
Testing effectiveness (Phase 2)Looking for participantsNCT06956716
What this trial is testing

Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma

Who this might be right for
Advanced Intrahepatic Cholangiocarcinoma
Zhejiang University 30
Testing effectiveness (Phase 2)Study completedNCT05223231
What this trial is testing

Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors

Who this might be right for
Advanced Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd 26
Early research (Phase 1)Study completedNCT03547037
What this trial is testing

Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers

Who this might be right for
Neoplasm
Janssen Pharmaceutical K.K. 22
Testing effectiveness (Phase 2)Looking for participantsNCT04777084
What this trial is testing

The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.

Who this might be right for
Non-Small Cell Lung Cancer
Hunan Province Tumor Hospital 120
Large-scale testing (Phase 3)Not Yet RecruitingNCT06255795
What this trial is testing

The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma

Who this might be right for
Extranodal Natural Killer T Cell Lymphoma
Ruijin Hospital 142
Testing effectiveness (Phase 2)Study completedNCT04672330
What this trial is testing

Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma

Who this might be right for
Neoadjuvant Immunotherapy of Cisplatin-ineligible High Risk Upper Urinary Tract Urothelial Carcinoma
RenJi Hospital 16
Testing effectiveness (Phase 2)Looking for participantsNCT05000892
What this trial is testing

Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms

Who this might be right for
Salivary Gland Malignant NeoplasmsSalivary Gland Tumors
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 15
Testing effectiveness (Phase 2)WithdrawnNCT05039736
What this trial is testing

A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy

Who this might be right for
Hepatocellular CarcinomaLiver Cancer
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT03111732
What this trial is testing

Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)

Who this might be right for
Biliary Tract NeoplasmsCholangiocarcinomaBile Duct Cancer+2 more
National Cancer Institute (NCI) 11
Testing effectiveness (Phase 2)UnknownNCT04164238
What this trial is testing

Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined With Chemotherapy in HNSCC Patients

Who this might be right for
Head and Neck Squamous Cell Carcinoma
First Affiliated Hospital of Zhejiang University 90
Testing effectiveness (Phase 2)Active Not RecruitingNCT06035224
What this trial is testing

Cadonilimab (AK104) Plus Lenvatinib in Previously Immunotherapy-Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma

Who this might be right for
Clear Cell Renal Cell Carcinoma
RenJi Hospital 28
Testing effectiveness (Phase 2)Looking for participantsNCT07253142
What this trial is testing

A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer

Who this might be right for
Non Small Cell Lung CancerSmall Cell Lung Cancer
Shanghai Henlius Biotech 120
Testing effectiveness (Phase 2)Study completedNCT04645069
What this trial is testing

ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors

Who this might be right for
Advanced/Metastatic Solid Tumors
Adagene Inc 58
Testing effectiveness (Phase 2)Looking for participantsNCT07005570
What this trial is testing

Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer （SPARK）

Who this might be right for
pMMR/MSS Locally Advanced Rectal Cancer
Dechang Diao 86
Not applicableUnknownNCT05164978
What this trial is testing

DEP Combine With PD-1 Antibody as an Treatment for EBV-HLH

Who this might be right for
Hemophagocytic Lymphohistiocytosis
Beijing Friendship Hospital 20
Early research (Phase 1)UnknownNCT03282435
What this trial is testing

Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody

Who this might be right for
Non-small Cell Lung Cancer
Dalian University 30
Testing effectiveness (Phase 2)Looking for participantsNCT07147348
What this trial is testing

A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
BioNTech SE 375
Testing effectiveness (Phase 2)Looking for participantsNCT06030258
What this trial is testing

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

Who this might be right for
Small Cell Lung Cancer Extensive Stage
InxMed (Shanghai) Co., Ltd. 120
Testing effectiveness (Phase 2)UnknownNCT04676789
What this trial is testing

Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL

Who this might be right for
Extranodal NK/T-cell Lymphoma, Nasal Type
Sun Yat-sen University 30
Next Page